Onyx Biotec Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹72 Cr
- ROE
- -0.38%
- Price to sales
- 1.03
- Debt to equity
- 0.27
- 52W high / low
- ₹48.4 / ₹28.6
- EBITDA margin
- 4.91%
- Net profit margin
- -0.30%
- Promoter holding
- 41.74%
- Sales (last year)
- ₹69 Cr
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Onyx Biotec shareholding (Sep 2026)
Promoters
41.74%
−23.36 pp QoQ
FIIs
0.22%
−0.85 pp QoQ
DIIs
2.39%
unchanged QoQ
Public
55.64%
+24.20 pp QoQ
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,142 Cr | 34.2 | |
| 2 | 40%+ | Up 2%+ | ₹489 Cr | 16.7 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,464 Cr | 1614.0 | |
| 5 | 40%+ | Flat | ₹9,050 Cr | 34.8 | |
| 6 | 40%+ | Flat | ₹4,493 Cr | — |
Sign up free to see every company in the sector ranking and track Onyx Biotec.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Onyx Biotec
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Onyx Biotec
Shareholding breakup across reporting periods.
| Nov 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Promoters + | 65.10% | 65.10% | 65.10% | 65.10% | 41.74% |
| FIIs + | 8.72% | 5.36% | 1.95% | 1.07% | 0.22% |
| DIIs + | 3.29% | 2.39% | 2.39% | 2.39% | 2.39% |
| Public + | 22.89% | 27.15% | 30.56% | 31.44% | 55.64% |
| No. of Shareholders | 1,181 | 551 | 640 | 586 | 631 |
Pros & Cons
Onyx Biotec
Key positives and risks surfaced from the company insights section.
- Promoter holding has decreased over last quarter: -23.4%
- Company has a low return on equity of 6.12% over last 3 years.
- Promoter holding has decreased over last quarter: -23.4%
- Company has a low return on equity of 6.12% over last 3 years.
Financials of Onyx Biotec
Quarterly Results
Quarter-by-quarter operating performance
Financials of Onyx Biotec
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales + | 44.86 | 39.49 | 53.75 | 61.95 | 69.47 | 78.29 |
| Sales growth | -11.97% | +36.11% | +15.26% | +12.14% | +17.92% | |
| Expenses + | 39.09 | 34.99 | 45.36 | 51.57 | 66.06 | 72.98 |
| Operating Profit | 5.77 | 4.50 | 8.39 | 10.38 | 3.41 | 5.31 |
| OPM % | 12.86% | 11.40% | 15.61% | 16.76% | 4.91% | 6.78% |
| Other Income + | 0.12 | 0.11 | 0.13 | 1.17 | 0.44 | 0.60 |
| Interest | 0.65 | 0.57 | 2.16 | 2.02 | 1.22 | 1.21 |
| Depreciation | 1.45 | 1.49 | 1.87 | 3.05 | 3.05 | 2.94 |
| Profit before tax | 3.79 | 2.55 | 4.49 | 6.48 | -0.42 | 1.76 |
| Tax % | 11.61% | 27.45% | 19.15% | 23.46% | -50.00% | |
| Net Profit + | 3.35 | 1.84 | 3.63 | 4.95 | -0.21 | 1.63 |
| EPS in Rs | 2.51 | 1.38 | 2.72 | 2.73 | -0.12 | 0.90 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Onyx Biotec
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 5.90 | 5.90 | 13.32 | 18.13 | 18.13 | 18.13 |
| Reserves | 10.47 | 12.30 | 11.97 | 37.49 | 37.28 | 38.22 |
| Borrowings + | 12.25 | 29.23 | 30.78 | 12.46 | 15.17 | 10.81 |
| Other Liabilities + | 8.22 | 11.30 | 18.07 | 23.17 | 24.58 | 26.23 |
| Total Liabilities | 36.84 | 58.73 | 74.14 | 91.25 | 95.16 | 93.39 |
| Fixed Assets + | 17.23 | 42.50 | 43.48 | 40.90 | 39.16 | 36.80 |
| CWIP | 4.02 | 0.00 | 0.00 | 0.00 | 3.68 | 6.23 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 15.59 | 16.23 | 30.66 | 50.35 | 52.32 | 50.36 |
| Total Assets | 36.84 | 58.73 | 74.14 | 91.25 | 95.16 | 93.39 |
Financials of Onyx Biotec
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 0.49 | 1.96 | 1.52 | 1.42 | -1.49 |
| Cash from Investing Activity + | -5.78 | -22.68 | -3.15 | 0.66 | -4.58 |
| Cash from Financing Activity + | 5.20 | 16.43 | 3.09 | 5.07 | 1.50 |
| Net Cash Flow | -0.09 | -4.30 | 1.46 | 7.15 | -4.57 |
| Free Cash Flow | -5.30 | -20.78 | -1.70 | 1.91 | -6.48 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 8% | 44% | 18% | 14% | -44% |
Financials of Onyx Biotec
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 68.51 | 46.95 | 104.37 | 119.19 | 144.49 |
| Inventory Days | 41.98 | 109.92 | 92.94 | 150.14 | 99.20 |
| Days Payable | 59.46 | 120.16 | 140.83 | 156.02 | 124.70 |
| Cash Conversion Cycle | 51.03 | 36.71 | 56.48 | 113.32 | 118.98 |
| Working Capital Days | 35.72 | -52.22 | 37.62 | 87.49 | 77.29 |
| ROCE % | 8.23% | 12.85% | 12.16% | 1.15% |
Onyx Biotec: frequently asked questions
What is Onyx Biotec share price today?
Onyx Biotec last traded at ₹39.55, with a market capitalisation of ₹72 Cr.
What is the promoter holding in Onyx Biotec?
Promoters held 41.74% of Onyx Biotec in Sep 2026 (−23.36 pp versus Mar 2026).
How much do FIIs and DIIs hold in Onyx Biotec?
In Sep 2026, foreign institutional investors held 0.22% and domestic institutions (including mutual funds) held 2.39% of Onyx Biotec.
What is Onyx Biotec's ROE and ROCE?
Onyx Biotec's return on equity is -0.38% and its return on capital employed is 1.15%.
Does Onyx Biotec pay a dividend?
Onyx Biotec's dividend yield is 0% at the current price; see the Onyx Biotec dividends page for past payouts.
Which sector does Onyx Biotec belong to?
Onyx Biotec is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Onyx Biotec's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Onyx Biotec's management.
How does Arthneeti AI analyse Onyx Biotec?
Arthneeti reads Onyx Biotec's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Onyx Biotec's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
